2022
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence.
Blasiak A, Truong A, Jeit L, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan L, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.Peer-Reviewed Original ResearchStandard-of-careSingle-agent capecitabineCapecitabine doseProspective feasibility trialClinical trialsChemotherapy doseSolid tumorsImprove patient response ratesDosing decisionsTreatment of solid tumorsIndividualize chemotherapy dosingAdvanced solid tumorsProspective clinical trialPatient response rateRandomized clinical trialsPrescribed dosePatient-specific variationsOpen-labelDosing recommendationsTumor markersOrgan dysfunctionPatient comorbiditiesDose selectionOncological indicationsCapecitabine
2021
Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial
Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.Peer-Reviewed Original ResearchTumor marker levelsRandomized controlled trialsChemotherapy doseSolid tumorsDrug doseDosing recommendationsMarker levelsAmerican Association for Cancer Research annual meetingsSignificant dose changesTumor marker measurementsCapecitabine-based chemotherapyMetastatic solid tumorsOptimal chemotherapy dosingRecruitment of patientsFrequent toxicitiesOpen-labelCA19-9Dose changesCohort expansionTumor markersSingle-armSuboptimal efficacyProportion of participantsChemotherapySerial measurementsPersonalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial
Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.Peer-Reviewed Original ResearchTumor marker levelsRandomised controlled trialsDrug dosePersonalised dosingSolid tumorsMarker levelsNational Healthcare GroupSignificant dose changesCapecitabine-based chemotherapyMetastatic solid tumorsDose of drugOpen-labelChemotherapy doseDose changesDosing recommendationsCohort expansionSingle-armSuboptimal efficacyProportion of participantsPrimary outcomeSecondary outcomesInterim analysisPhysician adherenceControlled trialsPrecision oncology